Evidence map›Paper›PMID 30066131›Full record

ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2018

Diagnosis and management of bone fragility in diabetes: an emerging challenge.

S L Ferrari, B Abrahamsen, N Napoli, K Akesson, M Chandran, R Eastell, G El-Hajj Fuleihan, R Josse, D L Kendler, M Kraenzlin and 5 more

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05613400 (The Effect of Simvastatin on Bone Density in Postmenopausal Women With Type 2 Diabetes), which is not on this map. Cited by 203 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
203citing papers in PubMed, 8 pooled it
29.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05613400 phase4unknown statusstarted 2022, after this paper: background citation

The Effect of Simvastatin on Bone Density in Postmenopausal Women With Type 2 Diabetes: a Double-blind, Randomized Active-comparator (Ezetimibe) Controlled Clinical Trial

Ran2022Enrolled240Registered outcomes7Posted comparisons0ConditionsDiabetes Mellitus, Type 2ArmsEzetimibe 10mg, Simvastatin 10mg
PMID 28434032PMID 10720052PMID 15317608PMID 17530471PMID 26969416PMID 27004165PMID 29496507PMID 30403505PMID 30615801PMID 11701680PMID 30674078PMID 31384961other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

203 citing papers in PubMed, 8 syntheses or guidelines pooled it, 382 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trabecular bone score in adults with type 1 diabetes: a meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Effects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2024
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Reduced postprandial bone resorption and greater rise in GLP-1 in overweight and obese individuals after an α-glucosidase inhibitor: a double-blinded randomized crossover trial.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021
    Trial
  14. Trial
  15. Glycemic Control and Insulin Treatment Alter Fracture Risk in Older Men With Type 2 Diabetes Mellitus.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019 · on this map
    Trial
  16. Prevalence, risk factors and adverse health outcomes of osteosarcopenia in middle-aged and older adults with type 2 diabetes mellitus-a scoping review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Review
  17. Demographic and clinical differences between individuals with and without DXA scans in Denmark.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  18. Review
  19. Article
  20. Review

143 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 10 countries.

S L FerrariDivision of Bone Diseases, Department of Internal Medicine Specialties, Geneva University Hospital & Faculty of Medicine, 1205, Geneva, Switzerland. serge.ferrari@unige.ch.
B AbrahamsenDepartment of Medicine, Holbaek Hospital, Holbaek, Denmark.
N NapoliUnit of Endocrinology and Diabetes, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy.
K AkessonDepartment of Clinical Sciences, Clinical and Molecular Osteoporosis Unit, Lund University, Malmö, Sweden.
M ChandranOsteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, Singapore, Singapore.
R EastellAcademic Unit of Bone Metabolism, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK.
G El-Hajj FuleihanDepartment of Internal Medicine, Division of Endocrinology, Calcium Metabolism and Osteoporosis Program, WHO Collaborating Center for Metabolic Bone Disorders, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon.
R JosseDepartment of Medicine and Department of Nutritional Sciences, University of Toronto, Toronto, ON, Canada.
D L KendlerDepartment of Medicine, Division of Endocrinology, University of British Columbia, Vancouver, BC, Canada.
M KraenzlinEndonet, Endocrine Clinic and Laboratory, Basel, Switzerland.
A SuzukiDivision of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi, Japan.
D D PierrozInternational Osteoporosis Foundation, Nyon, Switzerland.
A V SchwartzDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
W D LeslieDepartment of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Bone and Diabetes Working Group of IOF
Fujita Health University · JPSt. Michael's Hospital · CAUniversity of California, San Francisco · USUniversity of Manitoba · CAAmerican University of Beirut Medical Center · LBLund University · SESingapore General Hospital · SGUniversità Campus Bio-Medico · ITUniversity of British Columbia · CAUniversity of Geneva · CHUniversity of Sheffield · GBUniversity of Southern Denmark · DKUniversity Hospital of Geneva · CH

Funding

Department of Health 10/33/04Medical Research Council G0400491Medical Research Council G0601019Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UP_A620_1015Medical Research Council MC_UU_12011/1Medical Research Council MC_UU_12011/2Medical Research Council MR/P020941/1
6 · The paper itself

Abstract

Fragility fractures are increasingly recognized as a complication of both type 1 and type 2 diabetes, with fracture risk that increases with disease duration and poor glycemic control. Yet the identification and management of fracture risk in these patients remains challenging. This review explores the clinical characteristics of bone fragility in adults with diabetes and highlights recent studies that have evaluated bone mineral density (BMD), bone microstructure and material properties, biochemical markers, and fracture prediction algorithms (i.e., FRAX) in these patients. It further reviews the impact of diabetes drugs on bone as well as the efficacy of osteoporosis treatments in this population. We finally propose an algorithm for the identification and management of diabetic patients at increased fracture risk.

Indexed as

Bone Density Conservation AgentsBone RemodelingDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2HumansOsteoporosisOsteoporotic FracturesRisk FactorsBone Density Conservation AgentsDiabetesDiabetes-related bone diseaseFractureOsteoporosis

Identifiers

PMID30066131
PMCPMC6267152
OpenAlexW2885709578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.